Prenatal and Newborn Genetic Testing Market

Market Overview: 

The global prenatal and newborn genetic testing market size reached US$ 5.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.2 Billion by 2028, exhibiting a growth rate (CAGR) of 13.2% during 2023-2028. The growing demand for advanced diagnostic and screening devices, rising prevalence of congenital malformations and genetic abnormalities in newborn babies around the world, and thriving medical industry represent some of the key factors driving the market.

Prenatal and newborn genetic testing comprises blood tests, a specific type of ultrasound, and prenatal cell-free DNA screening that offers invaluable insights into the genetic makeup of unborn babies and newborns. It can identify certain birth defects, many of which are genetic disorders in unborn or newborn babies. It provides critical information to expectant parents, healthcare professionals, and researchers, enabling them to make informed decisions about the health and well-being of infants. It assists in improving patient outcomes and guiding medical interventions while enabling accurate identification of genetic variations and abnormalities during pregnancy and early infancy. It also aids in detecting various congenital conditions, such as Down syndrome, cystic fibrosis, sickle cell disease, and phenylketonuria. As it helps analyze various protein levels in the blood of parents to determine the risk for abnormal chromosome numbers in babies, the demand for prenatal and newborn genetic testing is rising across the globe. 

Prenatal and Newborn Genetic Testing Market Trends:

At present, the rising demand for advanced diagnostic and screening devices among the masses across the globe represents one of the key factors supporting the growth of the market. In addition, there is an increase in the prevalence of congenital malformations and genetic abnormalities in newborn babies worldwide. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the growing demand for non-invasive prenatal screening methods due to their various benefits, such as high accuracy and precision, less pain, and fast diagnosis, as compared to conventional methods, is positively influencing the market. Besides this, the rising awareness among individuals about the benefits of prenatal and newborn genetic testing is offering lucrative growth opportunities to industry investors. Additionally, the escalating demand for prenatal and newborn genetic testing due to the increasing number of health-conscious individuals is contributing to the growth of the market. Apart from this, governing agencies of various countries are focusing on improving healthcare infrastructure to provide enhanced healthcare services to citizens. In line with this, key players are developing genetic eye tests to identify the risk of keratoconus and other corneal dystrophies in patients. Furthermore, the growing demand for cell-free DNA in maternal plasma tests to detect the risk of genetic disorders is offering a favorable market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global prenatal and newborn genetic testing market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product type, screening, disease, and end user.

Product Type Insights:

• Consumables
• Instruments
   

The report has provided a detailed breakup and analysis of the prenatal and newborn genetic testing market based on the product type. This includes consumables and instruments. According to the report, consumables represented the largest segment.

Screening Insights:

• Non-invasive Prenatal Testing
• Chorionic Villus Sampling
• Amniocentesis
• Maternal Serum Screening
   

A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the screening has also been provided in the report. This includes non-invasive prenatal testing, chorionic villus sampling, amniocentesis, and maternal serum screening. According to the report, non-invasive prenatal testing accounted for the largest market share.

Disease Insights:

• Downs Syndrome
• Phenylketonuria
• Cystic Fibrosis
• Sickle Cell Anemia
   

A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the disease has also been provided in the report. This includes downs syndrome, phenylketonuria, cystic fibrosis, and sickle cell anemia. According to the report, downs syndrome accounted for the largest market share.

End User Insights:

• Hospital
• Maternity and Specialty Clinics
• Diagnostic Centers
   

A detailed breakup and analysis of the prenatal and newborn genetic testing market based on the end user has also been provided in the report. This includes hospital, maternity and specialty clinics, and diagnostic centers. According to the report, hospital accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for prenatal and newborn genetic testing. Some of the factors driving the North America prenatal and newborn genetic testing market included the growing number of pregnant women undergoing genetic screening, rising awareness about various inborn genetic diseases, enhanced healthcare infrastructure, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global prenatal and newborn genetic testing market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, BGI Group, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Incorporated, Ravgen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report. 

Report Coverage:

Key Questions Answered in This Report:

• How has the global prenatal and newborn genetic testing market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global prenatal and newborn genetic testing market?
• What is the impact of each driver, restraint, and opportunity on the global prenatal and newborn genetic testing market?
• What are the key regional markets?
• Which countries represent the most attractive prenatal and newborn genetic testing market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the prenatal and newborn genetic testing market?
• What is the breakup of the market based on the screening?
• Which is the most attractive screening in the prenatal and newborn genetic testing market?
• What is the breakup of the market based on the disease?
• Which is the most attractive disease in the prenatal and newborn genetic testing market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the prenatal and newborn genetic testing market?
• What is the competitive structure of the global prenatal and newborn genetic testing market?
• Who are the key players/companies in the global prenatal and newborn genetic testing market?

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the prenatal and newborn genetic testing market from 2017-2028.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global prenatal and newborn genetic testing market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the prenatal and newborn genetic testing industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.